


AMENDMENTS TO THE CLAIMS:

Please amend the claims as follows:

Claims 1-37. (Canceled)

38. (Currently Amended) A pharmaceutical composition, comprising one or more
~~in a pharmaceutically acceptable excipients or vehicles and support,~~ at least one
substituted 1,3-diphenylprop-2-en-1-one derivative represented by formula (I) below :



(I)

wherein :

X1 represents a halogen or a -R1 group or a group corresponding to the
following formula : -G1-R1,

X2 represents a hydrogen atom ~~or a hydroxy group or an unsubstituted alkoxy
group or a thiol group or an alkylthio group,~~

X3 represents a -R3 group ~~or a group corresponding to the following formula:-
G3-R3,~~

X4 represents a halogen ~~or a -R4 group~~ or a group corresponding to the
following formula: -G4-R4,

X5 represents a -R5 group ~~or a group corresponding to the following formula:-
G5-R5,~~

X6 is an oxygen atom ~~or a nitrogen atom, in the case where X6 is a nitrogen atom,~~ it carries a hydrogen atom ~~or a hydroxy group or an alkyloxy group,~~

R1, R3, [[R4,]]R5, which are the same or different, represent ~~a hydrogen atom or~~ an unsubstituted alkyl group having from one to seven carbon atoms ~~substituted or not by a substituent which is part of group 1 or group 2 defined hereinbelow,~~

G1, [[G3,]]G4, [[G5,]]which are the same or different, represent an oxygen or sulfur atom,

~~with at least one of the groups X1, X3, X4 or X5 corresponding to the formula -G-R in which G is a sulfur atom, and~~

~~with at least one of the groups R1, R3, R4 or R5~~ represents in the form of an alkyl group having from one to seven carbon atoms ~~containing at least one substituent from group 1 or 2,~~

~~the substituents from group 1 are selected in the group consisting of carboxy groups having the formula: -COOR₆ and carbamoyl groups having the formula: -CONR₆R_z,~~

~~the substituents from group 2 are selected in the group consisting of sulfonic acid (SO₃H) and sulfonamide groups having the formula: -SO₂NR₆R_z,~~

~~with R₆ and R_z, which are the same or different, representing a hydrogen atom or an alkyl group having from one to seven carbon atoms~~ possibly substituted by at least one group of type 1 or 2,

~~with the exception of compounds represented by formula (I) in which:~~

~~X₂ represents a hydrogen atom and X₁ represents G₁R₁ where G₁ represents an oxygen atom and R₁ represents CH₂COOH, and~~

the optical and geometrical isomers, racemates, tautomers, salts and mixtures thereof.

Claim 39. (Cancelled)

Claim 40. (Cancelled)

Claims 41 and 42. (Cancelled)

43. (Currently Amended) The composition according to claim 38 ~~or 39~~, wherein both G₁ and G₄ represent an oxygen-sulfur atom.

Claims 44-47. (Cancelled)

48. (Currently Amended) The composition according to claim 38 ~~or 39~~, wherein X₁ is a -G₁-R₁ group in which G₁ is an oxygen atom and R₁ is an unsubstituted alkyl group containing from two to seven carbon atoms.

49. (Currently Amended) The composition according to claim 38 ~~or 39~~, wherein X₁ represents ~~a -R₁ group or~~ a group corresponding to the formula -G₁-R₁, where G₁ represents a sulphur atom and R₁ is an unsubstituted alkyl group containing one or two carbon atoms~~substituted by a substituent which is part of group 2 and G₁.~~

Claims 50-54. (Cancelled)

55. (Currently Amended) The composition according to claim 38 ~~or 39~~, wherein X₄ is ~~a -G₄-R₄ group in which G₄ is an oxygen atom, and X₃ and~~ X₃ and X₅ respectively represent R₃ ~~or -G₃R₃, on the one hand, and R₅ or -G₅R₅, on the other hand, with R₃ and R₅ being alkyl groups having~~ one or two carbon atoms~~a substituent from group 4.~~

Claim 56. (Cancelled)

57. (Currently Amended) The composition according to claim 38-~~or~~39, wherein X1 represents a halogen.

Claim 58. (Cancelled)

59. (Currently Amended) The composition according to claim 38-~~or~~39, wherein X1, X3, X4 or X5 represents $\text{OC}(\text{CH}_3)_2\text{COOR}_6$ $\text{OC}(\text{CH}_3)_2\text{COOR}_6$.

60. (Currently Amended) The composition according to claim 38-~~or~~39, wherein X1, X3, X4 represents $\text{OC}(\text{CH}_3)_2\text{COOH}$ or X5 represents $\text{SC}(\text{CH}_3)_2\text{COOR}_6$.

61. (Currently Amended) The composition according to claim 38-~~or~~39, wherein the derivative is selected in the group consisting of:

1-[2-hydroxy-4-carboxydimethylmethoxyphenyl]-3-[3,5-di(~~tert~~butyl-4-hydroxyphenyl)]prop-2-en-1-one,

1-[2-hydroxy-4-ethyloxycarbonyldimethylmethoxyphenyl]-3-[3,5-di(~~tert~~butyl-4-hydroxyphenyl)]prop-2-en-1-one,

1-[2-hydroxyphenyl]-3-[3-carboxydimethylmethoxy-4-hydroxy-5-(~~tert~~butylphenyl)]prop-2-en-1-one,

1-[2-hydroxyphenyl]-3-[3-isopropylloxycarbonyldimethylmethoxy-4-hydroxy-5-(~~tert~~butylphenyl)]prop-2-en-1-one,

1-[2-hydroxy-4-chlorophenyl]-3-[3-carboxydimethylmethoxy-4-hydroxy-5-(~~tert~~butylphenyl)]prop-2-en-1-one,

1-[2-hydroxy-4-chlorophenyl]-3-[3-isopropylloxycarbonyldimethylmethoxy-4-hydroxy-5-(~~tert~~butylphenyl)]prop-2-en-1-one,

1-[2-hydroxyphenyl]-3-[3-carboxydimethylmethyl-4-hydroxy-5-
~~tert~~butylphenyl]prop-2-en-1-one,

1-[2-hydroxyphenyl]-3-[3-isopropylloxycarbonyldimethylmethyl-4-hydroxy-5-
~~tert~~butylphenyl]prop-2-en-1-one,

1-[2-hydroxy-4-chlorophenyl]-3-[3-carboxydimethylmethyl-4-hydroxy-5-
~~tert~~butylphenyl]prop-2-en-1-one,

1-[2-hydroxy-4-chlorophenyl]-3-[3-isopropylloxycarbonyldimethylmethyl-4-
hydroxy-5-~~tert~~butylphenyl]prop-2-en-1-one,

1-[2-hydroxy-4-chlorophenyl]-3-[3,5-dimethoxy-4-
carboxydimethylmethyloxyphenyl]prop-2-en-1-one,

1-[2-hydroxy-4-chlorophenyl]-3-[3,5-dimethoxy-4-
isopropylloxycarbonyldimethylmethyloxyphenyl]prop-2-en-1-one,

1-[2-hydroxyphenyl]-3-[3,5-dimethoxy-4-carboxydimethylmethyloxyphenyl]prop-2-
en-1-one,

1-[2-hydroxyphenyl]-3-[3,5-dimethoxy-4-isopropylloxycarbonyl
dimethylmethyloxyphenyl]prop-2-en-1-one,

1-[2-hydroxy-4-carboxydimethylmethyloxyphenyl]-3-[3,5-di-methoxy-4-
hydroxyphenyl]prop-2-en-1-one,

1-[2-hydroxy-4-isopropylloxycarbonyldimethylmethyloxyphenyl]-3-[3,5-dimethoxy-
4-hydroxyphenyl]prop-2-en-1-one,

1-[2-hydroxy-4-chlorophenyl]-3-[3,4-dihydroxy-5-
carboxydimethylmethyloxyphenyl] prop-2-en-1-one,

1-[2-hydroxy-4-chlorophenyl]-3-[3,4-dihydroxy-5-
isopropoxyloxycarbonyldimethylmethyloxyphenyl]-prop-2-en-1-one,

1-[2-hydroxy-4-carboxydimethylmethyloxyphenyl]-3-[3,5-dimethyl-4-
hydroxyphenyl]prop-2-en-1-one,

1-[2-hydroxy-4-isopropoxyloxycarbonyldimethylmethyloxyphenyl]-3-[3,5-dimethyl-4-
hydroxyphenyl]prop-2-en-1-one,

1-[2-hydroxy-4-chlorophenyl]-3-[3,5-dimethyl-4-
carboxydimethylmethyloxyphenyl]prop-2-en-1-one,

1-[2-hydroxy-4-chlorophenyl]-3-[3,5-dimethyl-4-
isopropoxyloxycarbonyldimethylmethyloxyphenyl]prop-2-en-1-one,

1-[2-hydroxyphenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-
en-1-one,

1-[2-hydroxyphenyl]-3-[3,5-dimethyl-4-isopropoxyloxycarbonyl
dimethylmethyloxyphenyl]prop-2-en-1-one,

1-[2-hydroxyphenyl]-3-[4-carboxydimethylmethylthiophenyl]prop-2-en-1-one,

1-[2-hydroxyphenyl]-3-[4-isopropoxyloxycarbonyldimethylmethylthiophenyl]prop-2-
en-1-one,

1-[2-hydroxy-4-ethoxycarbonyldimethylmethyloxyphenyl]-3-[3,5-ditertbutyl-4-
hydroxyphenyl]prop-2-en-1-one,

1-[2-hydroxy-4-carboxydimethylmethyloxyphenyl]-3-[4-methylthiophenyl]prop-2-
en-1-one,

1-[4-chlorophenyl]-3-[3,5-dimethyl-4-
tertbutyloxycarbonyldimethylmethoxyphenyl]prop-2-en-1-one,
1-[4-chlorophenyl]-3-[3,5-dimethyl-4-
isopropoxyloxycarbonyldimethylmethoxyphenyl]prop-2-en-1-one,
1-[4-chlorophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethoxyphenyl]prop-2-en-
1-one,
1-[2-hydroxyphenyl]-3-[4-carboxydimethylmethylthiophenyl]prop-2-en-1-one,
1-[4-chloro-2-hydroxyphenyl]-3-[4-carboxydimethylmethylthiophenyl]prop-2-en-1-
one,
1-[4-carboxydimethylmethoxyphenyl]-3-[3,5-dimethyl-4-hydroxyphenyl]prop-2-
en-1-one,
1-[4-methylthiophenyl]-3-[4-carboxydimethylmethoxyphenyl]prop-2-en-1-one,
1-[4-carboxydimethylmethylthiophenyl]-3-[4-methylthiophenyl]prop-2-en-1-one,
1-[2-hydroxy-4-bromophenyl]-3-[3,5-dimethyl-
4-carboxydimethylmethoxyphenyl]prop-2-en-1-one,
1-[4-carboxydimethylmethoxyphenyl]-3-[4-methylthiophenyl]prop-2-en-1-one,
1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-
tertbutyloxycarbonyldimethylmethoxyphenyl]prop-2-en-1-one,
1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-
isopropoxyloxycarbonyldimethylmethoxyphenyl]prop-2-en-1-one,
1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethoxyphenyl]prop-
2-en-1-one,

~~1-[2-methoxyphenyl]-3-[3,5-dimethyl-4-
tertbutyloxycarbonyldimethylmethyloxyphenyl]prop-2-en-1-one,~~

~~1-[2-methoxyphenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-
en-1-one,~~

~~1-[4-hexyloxyphenyl]-3-[3,5-dimethyl-4-
tertbutyloxycarbonyldimethylmethyloxyphenyl]prop-2-en-1-one,~~

~~1-[4-hexyloxyphenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-
en-1-one,~~

~~1-[2-methoxy-4-chlorophenyl]-3-[3,5-dimethyl-4-
tertbutyloxycarbonyldimethylmethyloxyphenyl]prop-2-en-1-one,~~

~~1-[2-methoxy-4-chlorophenyl]-3-[3,5-dimethyl-4-
carboxydimethylmethyloxyphenyl]prop-2-en-1-one,~~

~~1-[4-heptylphenyl]-3-[3,5-dimethyl-4-
tertbutyloxycarbonyldimethylmethyloxyphenyl]prop-2-en-1-one,~~

~~1-[4-heptylphenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-
1-one,~~

~~1-[4-bromophenyl]-3-[3,5-dimethyl-4-
tertbutyloxycarbonyldimethylmethyloxyphenyl]prop-2-en-1-one, and~~

~~1-[4-bromophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-
1-one.~~

62. (Currently Amended) The composition according to claim 38 or 39, wherein
the derivative is selected in the group consisting of:

1-[4-chlorophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethoxyphenyl]prop-2-en-

1-one.

1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethoxyphenyl]prop-2-en-1-one,

1-[4-hexyloxyphenyl]-3-[3,5-dimethyl-4-carboxydimethylmethoxyphenyl]prop-2-en-1-one, and

1-[4-bromophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethoxyphenyl]prop-2-en-1-one.

63. (Cancelled)

64. (Cancelled)

65. (Currently Amended) The composition according to claim 38 ~~or 39~~, wherein said composition is aimed for the treatment of a pathology related to deregulations of lipid and/or glucose metabolism-.

66. (Canceled)

67. (Cancelled)

68. (Withdrawn – Currently Amended) A method of treatment of pathologies related to deregulations of lipid and/or glucose metabolism comprising administering to a subject a composition as defined in claim 38 ~~or 39~~.

69. (Withdrawn – Currently Amended) A method for the treatment of diabetes, atherosclerosis or obesity comprising administering to a subject a composition according to claim 38 ~~or 39~~.